Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ischemic Heart Disease

Free Subscription Articles published in Thromb Haemost Retrieve available abstracts of 62 articles: HTML format Text format

Single Articles

July 2018
1. PEDICINO D, Giglio AF, Ruggio A, Massaro G, et al
   Inflammasome, T Lymphocytes and Innate-Adaptive Immunity Crosstalk: Role in Cardiovascular Disease and Therapeutic Perspectives.
   Thromb Haemost. 2018 Jul 10. doi: 10.1055/s-0038-1666860.
   PubMed     Text format     Abstract available
   
   
   June 2018
2. COELHO-LIMA J, Mohammed A, Cormack S, Jones S, et al
   Overcoming Heparin-Associated RT-qPCR Inhibition and Normalization Issues for microRNA Quantification in Patients with Acute Myocardial Infarction.
   Thromb Haemost. 2018 Jun 11. doi: 10.1055/s-0038-1660437.
   PubMed     Text format     Abstract available
   
   
   
3. ZAKAI NA, Judd SE, Kissela B, Howard G, et al
   Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS).
   Thromb Haemost. 2018 Jun 11. doi: 10.1055/s-0038-1655766.
   PubMed     Text format     Abstract available
   
   
   
4. VAN DER VORST EPC, Weber C, Donners MMPC
   A Disintegrin and Metalloproteases (ADAMs) in Cardiovascular, Metabolic and Inflammatory Diseases: Aspects for Theranostic Approaches.
   Thromb Haemost. 2018 Jun 6. doi: 10.1055/s-0038-1660479.
   PubMed     Text format     Abstract available
   
   
   
5. SUMAYA W, Parker WAE, Fretwell R, Hall IR, et al
   Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study).
   Thromb Haemost. 2018 Jun 6. doi: 10.1055/s-0038-1657768.
   PubMed     Text format     Abstract available
   
   
   
6. ALEXOPOULOS D, Xenogiannis I, Vlachakis P, Tantry U, et al
   Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention.
   Thromb Haemost. 2018 Jun 4. doi: 10.1055/s-0038-1649484.
   PubMed     Text format     Abstract available
   
   
   
7. CAPODANNO D, Greco A
   Risk Stratification for Bleeding in the Elderly with Acute Coronary Syndrome: Not So Simple.
   Thromb Haemost. 2018;118:949-952.
   PubMed     Text format    
   
   
   May 2018
8. BATUCA JR, Amaral MC, Favas C, Justino GC, et al
   Antibodies against HDL Components in Ischaemic Stroke and Coronary Artery Disease.
   Thromb Haemost. 2018 May 3. doi: 10.1055/s-0038-1645857.
   PubMed     Text format     Abstract available
   
   
   April 2018
9. PERTIWI KR, van der Wal AC, Pabittei DR, Mackaaij C, et al
   Neutrophil Extracellular Traps Participate in All Different Types of Thrombotic and Haemorrhagic Complications of Coronary Atherosclerosis.
   Thromb Haemost. 2018 Apr 19. doi: 10.1055/s-0038-1641749.
   PubMed     Text format     Abstract available
   
   
   
10. GARAY A, Ariza-Sole A, Formiga F, Raposeiras-Roubin S, et al
    Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry.
    Thromb Haemost. 2018 Apr 3. doi: 10.1055/s-0038-1635259.
    PubMed     Text format     Abstract available
    
    
    March 2018
11. CAMM AJ
    The Evolution of Antithrombotic Care in Cardiovascular Patients.
    Thromb Haemost. 2018 Mar 22. doi: 10.1055/s-0038-1626720.
    PubMed     Text format    
    
    
    
12. KANG J, Han JK, Ahn Y, Chae SC, et al
    Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
    Thromb Haemost. 2018;118:591-600.
    PubMed     Text format     Abstract available
    
    
    
13. ARIZA-SOLE A, Guerrero C, Formiga F, Aboal J, et al
    Global Geriatric Assessment and In-Hospital Bleeding Risk in Elderly Patients with Acute Coronary Syndromes: Insights from the LONGEVO-SCA Registry.
    Thromb Haemost. 2018;118:581-590.
    PubMed     Text format     Abstract available
    
    
    February 2018
14. MJELVA OR, Svingen GFT, Pedersen EKR, Seifert R, et al
    Fibrinogen and Neopterin Is Associated with Future Myocardial Infarction and Total Mortality in Patients with Stable Coronary Artery Disease.
    Thromb Haemost. 2018 Feb 19. doi: 10.1055/s-0038-1629912.
    PubMed     Text format     Abstract available
    
    
    
15. DE CARVALHO LP, Fong A, Troughton R, Yan BP, et al
    Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome.
    Thromb Haemost. 2018;118:415-426.
    PubMed     Text format     Abstract available
    
    
    January 2018
16. VON KANEL R, Meister-Langraf RE, Schmid JP, Barth J, et al
    Low Self-rated Health Is Related to Blood Hypercoagulability in Patients Admitted with Acute Myocardial Infarction.
    Thromb Haemost. 2018;118:54-62.
    PubMed     Text format     Abstract available
    
    
    
17. BURNLEY-HALL N, Abdul F, Androshchuk V, Morris K, et al
    Dietary Nitrate Supplementation Reduces Circulating Platelet-Derived Extracellular Vesicles in Coronary Artery Disease Patients on Clopidogrel Therapy: A Randomised, Double-Blind, Placebo-Controlled Study.
    Thromb Haemost. 2018;118:112-122.
    PubMed     Text format     Abstract available
    
    
    
18. LOWE GDO
    Self-related Health and Blood Hypercoagulability: A Possible Mechanism for Cardiovascular Risk.
    Thromb Haemost. 2018;118:4-5.
    PubMed     Text format    
    
    
    August 2017
19. ZAFAR MU, Zafar M, Baber U, Smith DA, et al
    Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
20. ANETSBERGER A, Blobner M, Haller B, Schmid S, et al
    Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    July 2017
21. HARADA Y, Michel J, Lohaus R, Mayer K, et al
    Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
22. SILLER-MATULA J, Lang IM, Schoergenhofer C, Roest M, et al
    Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    June 2017
23. CUBEDO J, Blasco A, Padro T, Ramaiola I, et al
    Molecular signature of coronary stent thrombosis: oxidative stress and innate immunity cells.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available
    
    
    
24. TEN CATE H, Hackeng TM, Garcia de Frutos P
    Coagulation factor and protease pathways in thrombosis and cardiovascular disease.
    Thromb Haemost. 2017;117:1265-1271.
    PubMed     Text format     Abstract available
    
    
    
25. SIBBING D, Angiolillo DJ, Huber K
    Antithrombotic therapy for acute coronary syndrome: Past, present and future.
    Thromb Haemost. 2017;117:1240-1248.
    PubMed     Text format     Abstract available
    
    
    
26. PREISSNER KT, Herwald H
    Extracellular nucleic acids in immunity and cardiovascular responses: between alert and disease.
    Thromb Haemost. 2017;117:1272-1282.
    PubMed     Text format     Abstract available
    
    
    April 2017
27. CHRISTERSSON C, Thulin A, Siegbahn A
    Microparticles during long-term follow-up after acute myocardial infarction. Association to atherosclerotic burden and risk of cardiovascular events.
    Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH16-11-0837.
    PubMed     Text format     Abstract available
    
    
    March 2017
28. CAMPO G, Vieceli Dalla Sega F, Pavasini R, Aquila G, et al
    Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
    Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-12-0973.
    PubMed     Text format     Abstract available
    
    
    
29. THOMAS MR, Angiolillo DJ, Bonaca MP, Ajjan RA, et al
    Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
    Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-09-0703.
    PubMed     Text format     Abstract available
    
    
    
30. TARANCON-DIEZ L, De Pablo-Bernal RS, Alvarez-Rios AI, Rosado-Sanchez I, et al
    CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0867.
    PubMed     Text format     Abstract available
    
    
    February 2017
31. 
    Erratum to Rutten et al. "Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention" (Thromb Haemost 2016; 115: 353-360).
    Thromb Haemost. 2017;117:641.
    PubMed     Text format    
    
    
    
32. ZEYMER U, Hohlfeld T, Vom Dahl J, Erbel R, et al
    Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).
    Thromb Haemost. 2017;117:625-635.
    PubMed     Text format     Abstract available
    
    
    
33. CHRISTOPOULOS C, Farag M, Sullivan K, Wellsted D, et al
    Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention.
    Thromb Haemost. 2017;117:457-470.
    PubMed     Text format     Abstract available
    
    
    
34. BIANCARI F, Brascia D, Onorati F, Reichart D, et al
    Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score.
    Thromb Haemost. 2017;117:445-456.
    PubMed     Text format     Abstract available
    
    
    
35. URBANSKI K, Ludew D, Filip G, Filip M, et al
    CD14+CD16++ "nonclassical" monocytes are associated with endothelial dysfunction in patients with coronary artery disease.
    Thromb Haemost. 2017 Feb 23. doi: 10.1160/TH16-08-0614.
    PubMed     Text format     Abstract available
    
    
    
36. ALLAN V, Honarbakhsh S, Casas JP, Wallace J, et al
    Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population based cohorts of 20 million participants.
    Thromb Haemost. 2017 Feb 23. doi: 10.1160/TH16-11-0825.
    PubMed     Text format     Abstract available
    
    
    
37. FREYNHOFER MK, Iliev L, Bruno V, Rohla M, et al
    Platelet turnover predicts outcome after coronary intervention.
    Thromb Haemost. 2017 Feb 23. doi: 10.1160/TH16-10-0785.
    PubMed     Text format     Abstract available
    
    
    
38. NIEZGODA P, Sikora J, Baranska M, Sikora A, et al
    Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study.
    Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0670.
    PubMed     Text format     Abstract available
    
    
    
39. PARK Y, Tantry US, Koh JS, Ahn JH, et al
    Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0744.
    PubMed     Text format     Abstract available
    
    
    
40. ASHER E, Frydman S, Katz M, Regev E, et al
    Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibitionin Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-09-0728.
    PubMed     Text format     Abstract available
    
    
    January 2017
41. CHATTERJEE M, Behrendt A, Schmid M, Beck S, et al
    Platelets as a novel source of Gremlin-1: Implications for thromboinflammation.
    Thromb Haemost. 2017;117:311-324.
    PubMed     Text format     Abstract available
    
    
    December 2016
42. ZAKAI NA, McClure LA, Judd SE, Kissela B, et al
    D-dimer and the Risk of Stroke and Coronary Heart Disease. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
    Thromb Haemost. 2016 Dec 22. doi: 10.1160/TH16-07-0519.
    PubMed     Text format     Abstract available
    
    
    
43. GAO J, Ma X, Zhang Y, Guo M, et al
    The role of microRNAs in prethrombotic status associated with coronary artery disease.
    Thromb Haemost. 2016 Dec 22. doi: 10.1160/TH16-07-0503.
    PubMed     Text format     Abstract available
    
    
    November 2016
44. SCHOOLING CM, Zhong Y
    Plasma levels of the anti-coagulation protein C and the risk of ischaemic heart disease. A Mendelian randomisation study.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
45. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
    Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available
    
    
    
46. KREUTZ RP, Schmeisser G, Maatman B, Schaffter A, et al
    Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention.
    Thromb Haemost. 2016.
    PubMed     Text format    
    
    
    October 2016
47. POURDJABBAR A, Hibbert B, Chong AY, Le May MR, et al
    A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    
48. FLIERL U, Zauner F, Sieweke JT, Berliner C, et al
    Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    September 2016
49. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on chronic Antiplatelet Treatment for Acute Coronary Syndr
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available
    
    
    
50. DARWICHE W, Bejan-Angoulvant T, Angoulvant D, Babuty D, et al
    Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    July 2016
51. WEBER C, Shantsila E, Hristov M, Caligiuri G, et al
    Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups "Atherosclerosis & Vascular Biology" and "Thrombosis".
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    
52. ANTIOCHOS P, Marques-Vidal P, Virzi J, Pagano S, et al
    Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    May 2016
53. SANTILLI F, Marchisio M, Lanuti P, Boccatonda A, et al
    Microparticles as new markers of cardiovascular risk in diabetes and beyond.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available
    
    
    March 2016
54. WHITE SJ, Newby AC, Johnson TW
    Endothelial erosion of plaques as a substrate for coronary thrombosis.
    Thromb Haemost. 2016;115:509-19.
    PubMed     Text format     Abstract available
    
    
    
55. MORBIDUCCI U, Kok AM, Kwak BR, Stone PH, et al
    Atherosclerosis at arterial bifurcations: evidence for the role of haemodynamics and geometry.
    Thromb Haemost. 2016;115:484-92.
    PubMed     Text format     Abstract available
    
    
    January 2016
56. KIM JS, Han DC, Jeong YH, Park DW, et al
    Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Thromb Haemost. 2016;115:213-21.
    PubMed     Text format     Abstract available
    
    
    
57. POHL J, Hendgen-Cotta UB, Rammos C, Luedike P, et al
    Targeted intracellular accumulation of macrophage migration inhibitory factor in the reperfused heart mediates cardioprotection.
    Thromb Haemost. 2016;115:200-12.
    PubMed     Text format     Abstract available
    
    
    
58. HERTLE E, Arts IC, van der Kallen CJ, Feskens EJ, et al
    The alternative complement pathway is longitudinally associated with adverse cardiovascular outcomes. The CODAM study.
    Thromb Haemost. 2016;115:446-57.
    PubMed     Text format     Abstract available
    
    
    
59. ASHER E, Fefer P, Sabbag A, Herscovici R, et al
    Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
    Thromb Haemost. 2016;115:433-8.
    PubMed     Text format     Abstract available
    
    
    
60. VERGALLO R, Aguirre AD, Abtahian F, Minami Y, et al
    Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
    Thromb Haemost. 2016;115:237-9.
    PubMed     Text format    
    
    
    
61. COLLET JP, Kerneis M, Hulot JS, O'Connor SA, et al
    Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
    Thromb Haemost. 2016;115:382-91.
    PubMed     Text format     Abstract available
    
    
    
62. RUTTEN B, Roest M, McClellan EA, Sels JW, et al
    Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention.
    Thromb Haemost. 2016;115:353-60.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: